MNKD Q4 2025 Earnings — MannKind Corporation Revenue & Financial Results | Market Cap Arena

MNKDMannKind Corporation

$813M

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$112M+45.8% YoY

Gross Profit

$88M78.5% margin

Operating Income

-$8M-6.9% margin

Net Income

-$16M-14.2% margin

EPS (Diluted)

$-0.05

QoQ Revenue Growth

+36.3%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$10M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$792M

Total Liabilities

$843M

Stockholders' Equity

-$51M

Cash & Equivalents

$75M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$112M	$77M	+45.8%
Gross Profit	$88M	$57M	+53.6%
Operating Income	-$8M	$26M	-129.0%
Net Income	-$16M	$7M	-314.9%

Revenue Segments

Product Revenue

$124M77%

Royalty

$34M21%

Service

$3M2%